Jakarta, hitclubapk3 Indonesia
—
The Ministry of Health (Kemenkes) is currently reviewing the use and financing of Glucagon-Like Peptide-1 (GLP-1) therapy for treating
obesity
in Indonesia.This step was taken following the publication of new guidelines from the World Health Organization (WHO) regarding this therapy.
Director of Prevention and Control of Non-Communicable Diseases at the Ministry of Health, Siti Nadia Tarmizi, revealed that obesity is now included in the top five health problems found in the free health check (CKG) program.This problem is often found in the adult to elderly age group.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
“The government is updating the National Clinical Practice Guidelines (PNPK) for obesity, including its management. So far, medication is given to obese patients who already have symptoms of other diseases such as heart problems or difficulty moving,” said Nadia in a written statement, Sunday (7/12) quoting DetikHealth.
Regarding the possibility of GLP-1 therapy being included in services covered by BPJS Health, Nadia emphasized that this decision must go through the Health Technology Assessment (HTA) assessment process.Apart from that, the government also needs to ensure the availability of GLP-1 drugs in the country.
The Ministry of Health is said to be collaborating with experts to get complete input regarding the use of drugs for obese patients.
Medically, GLP-1 is a hormone that plays a role in regulating metabolism, while GLP-1 Receptor Agonist is a drug commonly used to lower blood sugar, help with weight loss, reduce the risk of heart and kidney complications, and reduce mortality in type 2 diabetes patients.
Previously, WHO released guidelines for the use of GLP-1 therapy in response to increasing requests from various countries grappling with high obesity rates.
WHO Director General, Tedros Adhanom Ghebreyesus, highlighted the importance of access to this therapy and the readiness of the global health system.
“Obesity impacts all countries and is linked to 3.7 million deaths by 2024. Without decisive action, the number of obese sufferers is predicted to double by 2030,” he said on the WHO’s official website.
Tedros emphasized that obesity is a chronic disease that requires ongoing treatment.GLP-1 therapy is considered to be able to help millions of people, but it cannot stand alone without lifestyle changes.
“Obesity is not just an individual problem, but a societal challenge that requires multisectoral action,” said Tedros.
The Ministry of Health ensures that the study of the use of GLP-1 therapy will consider all aspects, from effectiveness and safety to the readiness of the national health financing system.
The final decision regarding the implementation of GLP-1 in Indonesia will be made after the entire evaluation and consultation process with experts is completed.
(tis/tis)
[Gambas:hitclubapk3 Video]
Read More: Gacor Logistics Sector, Isuzu Trucks Dominate Commercial Car Market
Read More: PHOTO: Australia Officially Bans Children Under 16 from Using Social Media
